Patients may experience nausea, vomiting, diarrhea, constipation, stomach pain, reduced appetite, fatigue, or other concerns
PEX-168 is a new agent of long-acting GLP-1R agonist, which is molecularly modified from EX via amino acid modification and PEGylation (119), the first GLP-1R agonist modified by PEG to achieve long-term pharmacological action (120, 121)
For patients with significant insulin resistance, type 2 diabetes, or metabolic syndrome, the dual-action mechanism often delivers noticeably stronger results
The 2024 Standards of Care in Diabetes does emphasize use of certain GLP-1 medications over others for certain goals
Again, the range reflects two different assumptions about how long anti-obesity medications prevent diabetes (four years or over a lifetime)